Dr Frank Bröseler presented results from the clinical trial „Effect of Curodont™ Repair in Patients with Buccal Carious Lesions: A randomised controlled Clinical Trial” at the Annual Congress of the DGZMK (Deutscher Zahnärztetag) in Frankfurt, Germany. The results from the practice based study demonstrate the clinical superiority of Curodont™ Repair compared to the gold-standard Duraphat® for the treatment of initial tooth decay.
The outcome validates the data from previous studies as it compares Curodont™ Repair with the presently most common treatment of fluoridation with Duraphat® in a split-mouth design. The control treatment can lead to an arrest of the caries progress, whereas the Guided Enamel Regeneration with Curodont™ Repair leads to a regression of caries.
“In our practice, the preservation of teeth has top priority. The option to effectively and safely regenerate enamel constitutes a huge step towards preservative dentistry. In this sense, the results of the clinical trial are truly revolutionary”, says Frank Bröseler, DDS principle investigator of the clinical trial.
About Curodont™ and the Curolox® Technology
The patented CUROLOX® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation or Guided Enamel Regeneration (GER) which enables the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the CUROLOX® Technology to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
